Rallybio Corp (RLYB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rallybio Corp (RLYB) has a cash flow conversion efficiency ratio of -0.159x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.98 Million) by net assets ($50.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Rallybio Corp net asset quality index to measure how much of total assets are equity-financed.
Rallybio Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rallybio Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Rallybio Corp (RLYB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Rallybio Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rallybio Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
In The F
KO:014990
|
0.009x |
|
AGF A/S
CO:AGF-B
|
-0.067x |
|
Nabaltec AG
F:NTG
|
-0.054x |
|
Chainqui Construction Development Co Ltd
TW:2509
|
-0.056x |
|
BioPorto
CO:BIOPOR
|
-0.249x |
|
OPPSTAR
KLSE:0275
|
0.029x |
|
Rand Mining Ltd
AU:RND
|
0.048x |
|
Reworld Media
PA:ALREW
|
0.128x |
Annual Cash Flow Conversion Efficiency for Rallybio Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rallybio Corp from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see RLYB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.96 Million | $-29.81 Million | -0.514x | +35.65% |
| 2024-12-31 | $61.65 Million | $-49.28 Million | -0.799x | -40.84% |
| 2023-12-31 | $106.18 Million | $-60.27 Million | -0.568x | -67.75% |
| 2022-12-31 | $169.32 Million | $-57.28 Million | -0.338x | -30.48% |
| 2021-12-31 | $175.60 Million | $-45.53 Million | -0.259x | -60.01% |
| 2020-12-31 | $136.00 Million | $-22.04 Million | -0.162x | +81.82% |
| 2019-12-31 | $16.86 Million | $-15.03 Million | -0.891x | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more